Efficacy of Encorelane in Enhancing Barrier Function and Reducing Aging Signs in Sensitive Skin

ABSTRACT Background Sensitive skin requires targeted care to improve barrier function, reduce inflammation, and manage neurovascular reactivity. Objective Encorelane, a novel ingredient blend of saccharide isomerate, ribose, and fructooligosaccharides, was evaluated for its efficacy in addressing sensitive skin and visible aging signs. Methods In vitro: A 3D epidermal model (EpiKutis) with Sodium Lauryl Sulfate (SLS) induction was used to assess cytokines (interleukin 1α [IL‐1α], interleukin 6 [IL‐6], interleukin 8 [IL‐8], tumor necrosis factor α [TNF‐α], prostaglandin E2 [PGE2]) and barrier markers (filaggrin [FLG], loricrin [LOR], transglutaminase 1 [TGM1]). Hydration was examined via aquaporin 3 (AQP3) expression levels. Anti‐wrinkle efficacy was tested against UVA/UVB exposure, evaluating collagen synthesis and skin matrix components (Collagen types I, III, IV, VII, XVII, Laminin 5, hyaluronic acid [HA], Chondroitin sulfate [CS]). In vivo: A 6‐week double‐blind, half‐face study in 23 sensitive‐skin subjects evaluated the clinical effects of Encorelane versus placebo on repair, redness, firmness, and wrinkles. Results In vitro: Compared to the control group, Encorelane significantly reduced the levels of IL‐1α, TNF‐α, IL‐6, IL‐8, and PGE2 ( p < 0.05), and significantly increased the levels of AQP3, FLG, LOR, TGM1, collagen types I, III, IV, VII, XVII, and laminin 5 ( p < 0.05). In vivo: Compared to the placebo, Encorelane significantly improved TEWL, R2, F4, and crow's feet wrinkles ( p < 0.05). Conclusion Encorelane effectively targets both inflammation and aging signs, supporting its use as a dermocosmetic solution for sensitive, aging‐prone skin.